– PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types –
– Preclinical Studies Suggest Role of CD166 Expression Level in Anti-Cancer Activity and Potential for Combination of CX-2009 with Immunotherapy –
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the presentation of clinical and preclinical data for CX-2009, a CD166 targeting Probody Drug Conjugate (PDC), at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia.
“Collectively, these data highlight the potential opportunity for CX-2009, a novel first-in-class CD166-targeting anti-cancer agent,” said Sean McCarthy, D. Phil., president, chief executive officer and chairman of CytomX. “In our first clinical dose escalation with CX-2009, we have seen clear evidence of tumor shrinkage in multiple cancers in heavily pretreated patients and an encouraging safety profile. The safety profile of CX-2009 is of particular note given the widespread expression of CD166 on normal tissues and suggests that CytomX masking technology can allow targeting of novel, broadly distributed antigens. Moreover, our preclinical and clinical research is revealing a relationship between target levels and anti-cancer activity, further validating CD166 as a potential new point of intervention in cancer treatment. In addition, our preclinical research into the combination of CX-2009 with a PD-1 Probody provides preliminary evidence for the potential of these two mechanisms to synergize with each other. Based on these integrated observations presented at AACR 2019, we are excited to advance CX-2009 to the next phase of development.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.